GOA Therapeutics appointed former Gilead Sciences executive Dean Hakanson as chief medical officer to guide its investigational drug GOA26 through upcoming human clinical trials for acute alcohol intoxication.
In Plain English: The Clinical Takeaway
- The Candidate: GOA26 is an intravenous drug designed to rapidly lower blood alcohol levels and bind a toxic byproduct of alcohol breakdown called acetaldehyde.
- The Mechanism: It combines an engineered enzyme that accelerates alcohol metabolism with a chemical scavenger to clear dangerous toxins from the bloodstream.
- The Timeline: The company plans to file an application with the U.S. Food and Drug Administration by the end of 2026 to start human testing in 2027.
Transitioning From Gilead to Acute Alcohol Treatment
Hakanson brings 40 years of experience across clinical practice and biopharmaceutical development to the West Palm Beach, Florida-based biotechnology company. Previously, he led U.S. medical affairs at Gilead Sciences during the launch of remdesivir, an antiviral treatment deployed for hospitalized COVID-19 patients. His career also includes senior leadership roles at Novartis, Bristol Myers Squibb, Genentech, and GlaxoSmithKline.
Before entering biopharma executive leadership, Hakanson practiced as a board-certified anesthesiologist treating patients in trauma surgery and critical care environments.
Having treated dangerously intoxicated patients who presented at the trauma center, I know firsthand the clear unmet medical need and how desperately our healthcare system needs a drug to treat acute alcohol intoxication.
As chief medical officer, Hakanson will chair the GOA26 Drug Development Board, advise on clinical trial design, and direct medical affairs strategy while engaging with physicians and researchers.
Preclinical Data and Emergency Department Focus
GOA26 is engineered for intravenous delivery specifically inside hospital emergency departments and trauma centers. The therapy combines an engineered enzyme intended to accelerate the breakdown of alcohol with a compound designed to capture acetaldehyde, a potentially toxic byproduct of alcohol metabolism.
The company first unveiled the candidate in September at the 85th Annual Meeting of the American Association for the Surgery of Trauma in Dallas. In preclinical studies using a porcine model administered an oral ethanol dose of 1.2 grams per kilogram, animals treated with GOA26 recorded blood alcohol concentrations 61.3 percent lower than untreated control groups twenty minutes after administration.
| Parameter | Preclinical Finding (Porcine Model) |
|---|---|
| Ethanol Dose | 1.2 g/kg oral administration |
| Time Elapsed | 20 minutes post-administration |
| Blood Alcohol Concentration | 61.3% lower in treated animals vs. controls |
Regulatory Milestones and Financial Capitalization
GOA Therapeutics intends to submit an Investigational New Drug application to the U.S. Food and Drug Administration by the close of 2026. Human clinical trials are targeted to begin in 2027, pending regulatory clearance. GOA26 remains in preclinical development, and its safety and efficacy in humans have not been established.
To support its pipeline development, the company launched online stock offerings aimed at raising up to $300 million. This total encompasses up to $75 million under a Tier 2 Regulation A offering alongside up to $225 million in separate exempt offerings, representing potential fundraising capacity rather than secured capital.
Investigational Drug Not Available for Human Use
Because GOA26 is currently an investigational drug undergoing preclinical testing, it is not available for clinical use, and no specific human contraindications or dosage guidelines have been established by regulatory authorities.
